Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
62 hedge funds and large institutions have $667M invested in Principia Biopharma Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
25% more capital invested
Capital invested by funds: $534M → $667M (+$133M)
17% more funds holding
Funds holding: 53 → 62 (+9)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$77.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$10.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.39M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.41M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMPI
Morgenthaler Management Partners IX
Portola Valley,
California
|
-$60.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.59M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$4.01M |
| 4 |
RI
RTW Investments
New York
|
-$3.18M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.99M |
PRNB Hedge Fund Activity: Q1 2019 in Review
62 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q1 2019, worth a combined $667M — up 25% from $534M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRNB positions and 5 closed out — a net gain of 9 holders — while 16 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $77.5M. The largest seller was Morgenthaler Management Partners IX, exiting entirely with an estimated $60.1M sold.
- 62 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q1 2019, up from 53 in Q4 2018.
- Funds reported $667M of Principia Biopharma Inc. Common Stock stock for Q1 2019, up 25% quarter-over-quarter.
- 14 funds opened new Principia Biopharma Inc. Common Stock positions in Q1 2019 and 5 closed out, a net change of +9 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q1 2019 was Fidelity Investments, an estimated $77.5M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q1 2019 was Morgenthaler Management Partners IX, an estimated $60.1M sold.
Based on aggregated 13F filings for Q1 2019.